. A B Figure S8 . Characterization of unconjugated and vitamin B 12 -conjugated nanoparticles by Dynamic Light Scattering (DLS). A) DLS intensity distribution of unmodified YO nanoparticles with nominal diameters of 50 nm, 100 nm and 200 nm. B) DLS intensity distribution of vitamin B 12 -conjugated nanoparticles. Measurements were taken at 25°C in Hank's Balanced Salt Solution (biological solution in which nanoparticles were applied to the cells). The data represent a mean of 10 measurements. The DLS data is expressed as average hydrodynamic radii, which for unmodified nanoparticles were 21, 40 and 70 nm for nanoparticles with a nominal diameter of 50, 100 and 200 nm, respectively. For B 12 -conjugated nanoparticles, the measured hydrodynamic radii were 39, 100 and 139 nm for nanoparticles with a nominal, pre-conjugation diameter of 50, 100 and 200 nm, respectively. Figure S11 . Effect of pathway inhibitors, chlorpromazine (applied at 10 µg/ml) and filipin (applied at 5 µg/ml) on (A) cell uptake and (B) transport of unmodified nanoparticles (50 nm). Statistical comparison between 'Chlorpromazine (10µg/ml) treated and 'untreated 50nm nanoparticles' and 'Filipin (5µg/ml) treated' and 'untreated 50nm nanoparticles'. Statistical comparison between chlorpromazine or filipin treated with 'untreated 50nm nanoparticles'; 'ns' = non significant.
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